Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy

2 Aug 2024

Abstract excerpt

BACKGROUND: Immune checkpoint therapy (ICT) provides durable responses in select cancer patients, yet resistance remains a significant challenge, prompting the exploration of underlying molecular mechanisms. Tyrosylprotein sulfotransferase-2 (TPST2), known for its role in protein tyrosine O-sulfation, has been suggested to modulate the extracellular protein-protein interactions, but its specific role in cancer...

Topics

Join the communities discussing this publication.

Cancer Immunotherapy and Biomarkers
Protein Tyrosine Phosphatases
Tryptophan and brain disorders

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39095793
DOI: 10.1186/s12943-024-02068-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacyPMID 39095793Read ↗

Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancerSemantic proximity Read ↗

CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.Semantic proximity Read ↗

Pan-cancer analysis of HS6ST2: associations with prognosis, tumor immunity, and drug resistanceSemantic proximity Read ↗

In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancerSemantic proximity Read ↗

PRMT1 acts as a suppressor of MHC-I and anti-tumor immunitySemantic proximity Read ↗

Somatic <i>TYK2</i> activating mutations in tumor-infiltrating T cells promote anti-cancer immunitySemantic proximity Read ↗

Ex vivo and in vivo CRISPR/Cas9 screenings identify the roles of protein N-glycosylation in regulating T-cell activation and functionsSemantic proximity Read ↗

Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsSemantic proximity Read ↗

Massively parallel interrogation of human functional variants modulating cancer immunosurveillance.Semantic proximity Read ↗

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockadeSemantic proximity Read ↗

In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumorsSemantic proximity Read ↗

Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.